Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
5 NC counties are under alert, including Johnston County.
Program
Friday at 6 on WRAL: How much does your county spend on education? WRAL Investigates which counties are prioritizing your children.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sierra Oncology Inc
(NQ:
SRRA
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 30, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sierra Oncology Inc
< Previous
1
2
3
Next >
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 18, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 04, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 03, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Raises $135M Via Equity To Fund Lead Program Development
January 27, 2022
Sierra Oncology Inc (NASDAQ: SRRA) has priced its underwritten public offering of 4.07 million shares at $27 per share and the pre-funded warrants at $26.999 per pre-funded warrant.
Via
Benzinga
Sierra Oncology to Participate in Guggenheim Oncology Conference
February 03, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Closing of Upsized Public Offering of $135.0 Million of Securities
January 31, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology to Present at B. Riley Securities Oncology Investor Conference
January 27, 2022
From
Sierra Oncology
Via
Business Wire
R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug Treatments
January 27, 2022
Palm Beach, FL – January 27, 2022 – FinancialNewsMedia.com News Commentary – According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018,...
Via
FinancialNewsMedia
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
41 Biggest Movers From Yesterday
January 27, 2022
Gainers Ebang International Holdings Inc. (NASDAQ: EBON) shares gained 35.4% to settle at $1.09 on Wednesday as investors weighed the Federal Reserve Reserve decision to leave...
Via
Benzinga
Sierra Oncology Announces Pricing of Upsized Public Offering of Securities
January 26, 2022
From
Sierra Oncology
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 26, 2022
Gainers Reneo Pharmaceuticals (NASDAQ:RPHM
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 26, 2022
Gainers Rani Therapeutics Hldgs (NASDAQ:RANI
Via
Benzinga
32 Stocks Moving In Wednesday's Mid-Day Session
January 26, 2022
Gainers Exela Technologies, Inc. (NASDAQ: XELA) rose 32% to $0.7262 after the company announced a share buyback of up to 100 million shares of common stock at $1 per share...
Via
Benzinga
The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data
January 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
18 Stocks Moving in Wednesday's Pre-Market Session
January 26, 2022
Gainers Exicure, Inc. (NASDAQ: XCUR) rose 41.1% to $0.23 in pre-market trading after gaining around 4% on Tuesday. Barfresh Food Group, Inc. (NASDAQ: BRFH) shares rose 31.7% to $...
Via
Benzinga
51 Biggest Movers From Yesterday
January 26, 2022
Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares climbed 46.2% to close at $22.68 on Tuesday after the company unveiled topline data for momelotinib in myelofibrosis patients...
Via
Benzinga
Sierra Oncology Announces Proposed Public Offering of Common Stock
January 25, 2022
From
Sierra Oncology
Via
Business Wire
Mid-Afternoon Market Update: Dow Turns Higher; General Electric Shares Slide
January 25, 2022
Toward the end of trading Tuesday, the Dow traded up 0.12% to 34,405.65 while the NASDAQ fell 1.19% to 13,690.05. The S&P also fell, dropping, 0.57% to 4,384.81. The U.S...
Via
Benzinga
Mid-Day Market Update: Nasdaq Tumbles 300 Points; Sierra Oncology Shares Jump
January 25, 2022
Midway through trading Tuesday, the Dow traded down 1.15% to 33,968.17 while the NASDAQ fell 2.20% to 13,549.98. The S&P also fell, dropping, 1.68% to 4,336.24. The U.S. has...
Via
Benzinga
28 Stocks Moving In Tuesday's Mid-Day Session
January 25, 2022
Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares jumped 47.8% to $22.93 after the company unveiled topline data for momelotinib in myelofibrosis patients who are symptomatic,...
Via
Benzinga
Sierra Oncology's Bet On A Failed Gilead Drug Just Paid Off In A Big Way
January 25, 2022
Sierra Oncology spent just $3 million up front to acquire momelotinib.
Via
Investor's Business Daily
Sierra Oncology Secures Debt Facility Of Up To $125M With Oxford Finance To Support Momelotinib Development
January 25, 2022
Sierra Oncology Inc (NASDAQ: SRRA) has entered into a term loan agreement with Oxford Finance LLC to support the commercial preparation and potential...
Via
Benzinga
Sierra Oncology Shares Rally As Bone Marrow Cancer Candidate Hits Primary Goal
January 25, 2022
Sierra Oncology Inc (NASDAQ: SRRA) unveiled topline data for momelotinib in myelofibrosis patients who are symptomatic, anemic, and previously treated with an FDA-...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 25, 2022
Gainers Sierra Oncology (NASDAQ:SRRA) stock rose 45.6% to $22.58 during Tuesday's pre-market session. The market value of their outstanding shares is at $339.9 million...
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data
January 25, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate Pfizer,...
Via
Benzinga
Sierra Oncology Provides Financial Update to Support the Future Commercialization of Momelotinib
January 25, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis
January 25, 2022
From
Sierra Oncology
Via
Business Wire
Momelotinib Review Article Published in Journal of Hematology & Oncology Highlights Importance of Anemia Benefit for Myelofibrosis Patients
January 19, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Updates Topline Data Timing for Pivotal Phase 3 Trial of Momelotinib in Myelofibrosis
January 18, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 07, 2022
From
Sierra Oncology
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.